819 related articles for article (PubMed ID: 28319068)
21. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
22. DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-β/SMAD4 signaling.
Chan DW; Hui WW; Wang JJ; Yung MM; Hui LM; Qin Y; Liang RR; Leung TH; Xu D; Chan KK; Yao KM; Tsang BK; Ngan HY
Oncogene; 2017 Mar; 36(10):1404-1416. PubMed ID: 27593933
[TBL] [Abstract][Full Text] [Related]
23. Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer.
Ye H; Liu X; Sun J; Zhu S; Zhu Y; Chang S
BMC Cancer; 2016 Oct; 16(1):831. PubMed ID: 27793127
[TBL] [Abstract][Full Text] [Related]
24. The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells.
Thériault BL; Cybulska P; Shaw PA; Gallie BL; Bernardini MQ
J Ovarian Res; 2014 Dec; 7():123. PubMed ID: 25528264
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells.
Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G
Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456
[TBL] [Abstract][Full Text] [Related]
26. Serine hydroxymethyl transferase 1 stimulates pro-oncogenic cytokine expression through sialic acid to promote ovarian cancer tumor growth and progression.
Gupta R; Yang Q; Dogra SK; Wajapeyee N
Oncogene; 2017 Jul; 36(28):4014-4024. PubMed ID: 28288142
[TBL] [Abstract][Full Text] [Related]
27. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
[TBL] [Abstract][Full Text] [Related]
28. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
[TBL] [Abstract][Full Text] [Related]
29. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice.
Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V
Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932
[TBL] [Abstract][Full Text] [Related]
30. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
31. AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer.
Kobayashi A; Tanizaki Y; Kimura A; Ishida Y; Nosaka M; Toujima S; Kuninaka Y; Minami S; Ino K; Kondo T
Eur J Pharmacol; 2015 Nov; 766():63-75. PubMed ID: 26410360
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
33. Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo.
Goyeneche AA; Carón RW; Telleria CM
Clin Cancer Res; 2007 Jun; 13(11):3370-9. PubMed ID: 17545545
[TBL] [Abstract][Full Text] [Related]
34. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
35. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
Kioi M; Takahashi S; Kawakami M; Kawakami K; Kreitman RJ; Puri RK
Cancer Res; 2005 Sep; 65(18):8388-96. PubMed ID: 16166317
[TBL] [Abstract][Full Text] [Related]
36. Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
Mo L; Pospichalova V; Huang Z; Murphy SK; Payne S; Wang F; Kennedy M; Cianciolo GJ; Bryja V; Pizzo SV; Bachelder RE
PLoS One; 2015; 10(7):e0131579. PubMed ID: 26148191
[TBL] [Abstract][Full Text] [Related]
37. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Hashimoto K; Morishige K; Sawada K; Tahara M; Kawagishi R; Ikebuchi Y; Sakata M; Tasaka K; Murata Y
Cancer Res; 2005 Jan; 65(2):540-5. PubMed ID: 15695397
[TBL] [Abstract][Full Text] [Related]
38. Sohlh2 inhibits human ovarian cancer cell invasion and metastasis by transcriptional inactivation of MMP9.
Zhang H; Hao C; Wang Y; Ji S; Zhang X; Zhang W; Zhao Q; Sun J; Hao J
Mol Carcinog; 2016 Jul; 55(7):1127-37. PubMed ID: 26153894
[TBL] [Abstract][Full Text] [Related]
39. Iron overload and altered iron metabolism in ovarian cancer.
Rockfield S; Raffel J; Mehta R; Rehman N; Nanjundan M
Biol Chem; 2017 Aug; 398(9):995-1007. PubMed ID: 28095368
[TBL] [Abstract][Full Text] [Related]
40. Iron and Cancer: 2020 Vision.
Torti SV; Torti FM
Cancer Res; 2020 Dec; 80(24):5435-5448. PubMed ID: 32928919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
